ARS PharmaceuticalsSPRY
SPRY
About: ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Employees: 24
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
277% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 13
148% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 23
74% more capital invested
Capital invested by funds: $533M [Q2] → $928M (+$395M) [Q3]
54% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $9.25M
50% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]
32% more funds holding
Funds holding: 114 [Q2] → 150 (+36) [Q3]
1.39% more ownership
Funds ownership: 64.69% [Q2] → 66.08% (+1.39%) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$30
168%
upside
Avg. target
$30
168%
upside
High target
$30
168%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Josh Schimmer 37% 1-year accuracy 22 / 59 met price target | 168%upside $30 | Overweight Reiterated | 8 Oct 2024 |
Financial journalist opinion
Based on 3 articles about SPRY published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions
Neutral
GlobeNewsWire
1 week ago
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies
Neutral
GlobeNewsWire
2 weeks ago
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy® ( epinephrine nasal spray) 2mg for use in emergency treatment of allergic reactions including anaphylaxis
Neutral
Seeking Alpha
1 month ago
ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Alex Straus - Investor Relations Richard Lowenthal - Co-Founder, President and CEO Eric Karas - Chief Commercial Office Kathleen Scott - CFO Justin Chakma - Chief Business Officer Conference Call Participants Josh Schimmer - Cantor Fitzgerald Ryan Deschner - Raymond James Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Operator Good day, and welcome to the ARS Pharmaceuticals Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
1 month ago
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.16 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Commercial launch of neffy ® (epinephrine nasal spray) underway in the United States Supplemental NDA for neffy ® 1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025 Exclusive license agreement with ALK-Abelló to commercialize neffy ® in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $465 million plus double-digit royalties Well-capitalized with $349.6 million in cash, cash equivalents and short-term investments on a pro forma basis, supporting an operating runway of at least three years Company to host conference call and webcast today at 8:00 a.m. ET
Positive
Investors Business Daily
1 month ago
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray
ARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally. The post ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray appeared first on Investor's Business Daily.
Positive
Benzinga
1 month ago
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024
On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. SPRY.
Neutral
GlobeNewsWire
1 month ago
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales ARS Pharma retains all U.S. rights, and existing partnerships in Japan, China, Australia and New Zealand with Alfresa, Pediatrix and CSL, respectively SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced a licensing agreement with ALK-Abelló A/S (“ALK”, Nasdaq: ALK B), that provides ALK exclusive rights to commercialize neffy ® (epinephrine nasal spray) (trade name EUR neffy ® in Europe), the first and only needle-free emergency treatment for Type I allergic reactions including anaphylaxis, in Europe, Canada and other geographies outside of the U.S. ARS Pharma retains all rights to neffy in the U.S., and there are no changes to its existing partnerships in Japan, China, Australia and New Zealand. “ALK is a specialized pharmaceutical company and a global leader in the allergy field, serving millions of allergy patients across 46 countries.
Neutral
GlobeNewsWire
1 month ago
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK's new strategy Allergy+ and supports ALK's long-term financial ambitions.
Charts implemented using Lightweight Charts™